Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Daratumumab-based regimens in newly diagnosed mayo 2004 stage 3b AL amyloidosis: A systematic review

View Full Paper
Ask AI
Bookmark
Share

Authors

YGYajuan GaoKYKaili YangXWXuezhu Wang

Discussion

Loading...

Member takes

Overview

Systematic review highlights improved hematologic response and survival rates in newly diagnosed AL amyloidosis patients treated with daratumumab.

Key Points

  • Promising hematologic response found with daratumumab treatment in patients with AL amyloidosis, improving outcomes.
  • Response rates showed a significant increase, particularly in hematologic responses among stage 3b patients.
  • Retrospective and prospective analyses indicate better overall survival in daratumumab vs bortezomib regimens.
  • Findings suggest the need for ongoing assessment of treatment safety, particularly regarding severe adverse events like cytopenias.

Cite This Study

Gao et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e07dhttps://doi.org/10.1182/blood-2025-7499
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic analysis of newly diagnosed systemic light-chain amyloidosis patients treated with daratumumab2025
  2. 2Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy2025
  3. 3Daratumumab in AL amyloidosis: survival, cardiac CR, and beyond2026
  4. 4Real-world outcomes of daratumumab in light-chain amyloidosis patients with advanced renal failure: A TriNetX network study.2026
  5. 5Real-world outcomes of standard and modified daratumumab-based therapy in AL amyloidosis: A cohort study from a multidisciplinary program in south India2025